Galvanize Therapeutics

Designs pulsed electric field energy devices for the surgical ablation of soft tissue and chronic disease.

Website: https://galvanizetx.com/

Cover Block

PUBLIC

Field Value
Name Galvanize Therapeutics
Tagline Designs pulsed electric field energy devices for the surgical ablation of soft tissue and chronic disease. [Galvanize Therapeutics, retrieved]
Headquarters Redwood City, United States [Galvanize Therapeutics, retrieved]
Founded 2015 [Galvanize Therapeutics, retrieved]
Stage Series D+ [PRNewswire, Nov 2026]
Business Model Hardware + Software
Industry Healthtech
Technology Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale
Founding Team Co-Founders (2): Seth Harrison, MD; Jonathan Waldstreicher, M.D. [Galvanize Therapeutics, retrieved]
Funding Label $100M+
Total Disclosed ~$330,000,000, based on disclosed Series B, Series C, and Series D rounds [Crunchbase News, Nov 2022] [StartupsRaised, Nov 2026] [PRNewswire, Nov 2026]

Links

Publicly reported

Summary and Signal

PUBLIC Galvanize Therapeutics builds pulsed electric field, or PEF, devices for soft-tissue ablation, and it merits investor attention now because it has both a commercial product in market and a funded path to expand into adjacent oncology and chronic disease indications [Galvanize Therapeutics, retrieved] [Finsmes, Nov 2026] [PRNewswire, Nov 2026]. The company traces its current form to a 2022 combination of Gala Therapeutics and Galaxy Medical, while its founding dates to 2015, which matters because the story is less about a new platform debut than about consolidating clinical and device programs under one capital structure [Crunchbase News, Nov 2022] [Galvanize Therapeutics, retrieved].

Its lead commercial platform, Aliya, is cleared in the United States for the surgical ablation of soft tissue, and company materials describe the mechanism as brief high-voltage pulses intended to induce nonthermal regulated cell death rather than heat-based destruction [Galvanize Therapeutics, retrieved] [Galvanize Therapeutics, Nov 2026]. That positioning is technically interesting, but the public proof points remain early by large-cap medtech standards: reporting in November 2026 cited more than 4,000 procedures on Aliya, more than 300 patients enrolled in the PROPEL registry, and a next-generation Aliya EX Generator that began commercial procedures in August 2026 [Finsmes, Nov 2026] [Citybiz, Nov 2026] [Dealroom, Nov 2026].

The founder record is partly company-sourced, with Seth Harrison, MD and Jonathan Waldstreicher, M.D. identified as co-founders, while leadership has since shifted, with Doug Godshall reported as CEO and chairman in 2025 [Galvanize Therapeutics, retrieved] [Apple Tree Partners, retrieved] [Citybiz, Nov 2026]. On the balance of evidence, this looks like a company pairing clinical credibility and device-development continuity with later-stage operating leadership, though the public materials stop short of giving a full operating history for each founder [Galvanize Therapeutics, retrieved] [Citybiz, Nov 2026].

Capital formation has been substantial: Crunchbase News reported a $100 million Series B in 2022, StartupsRaised reported a $100 million Series C led by Sofinnova Partners in 2025, and the company announced a $130 million Series D led by HealthQuest Capital in November 2026, implying roughly $330 million of disclosed funding across the rounds cited here [Crunchbase News, Nov 2022] [StartupsRaised, retrieved] [PRNewswire, Nov 2026]. The business model is hardware plus software sold into physicians and hospitals, and the next 12 to 18 months should turn on whether Galvanize can translate procedure volume and registry activity into broader adoption while advancing RheOx through pivotal evidence generation in chronic bronchitis [DFXIntel, retrieved] [ClinicalTrials.gov, retrieved 2026] [American Lung Association, retrieved 2026].

One source, partially checked -- This section relies on a mix of company materials, financing coverage, and registry or trial sources, with several core product and founder claims still primarily company-sourced.

Taxonomy Snapshot

Axis Value
Stage Series D+
Business Model Hardware + Software
Industry / Vertical Healthtech
Technology Type Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale
Founding Team Co-Founders (2)
Funding $100M+ (total disclosed ~$330,000,000)

Company Overview

PUBLIC

Galvanize Therapeutics presents as a Redwood City, California medical device company built around pulsed electric field, or PEF, ablation, with a public description centered on surgical treatment of soft tissue rather than a broader platform claim [Galvanize Therapeutics]. The company traces its founding to 2015 in available company and database profiles, and its website says it designs PEF energy devices for the surgical ablation of soft tissue [Galvanize Therapeutics] [Crunchbase].

The cleaner way to read the timeline is that Galvanize has an older founding date but a more recent operating configuration. Company materials say Galvanize was formed in 2022 through the merger of Gala Therapeutics and Galaxy Medical, and Crunchbase News reported the same year that the combined business raised $100 million in a Series B financing tied to that merger event [Galvanize Therapeutics] [Crunchbase News, Nov 2022].

Since that combination, the public milestones are mostly financing and leadership related. Crunchbase News reported the $100 million Series B in 2022, while later coverage identifies Doug Godshall as CEO and chairman from 2025 onward [Crunchbase News, Nov 2022] [Crunchbase]. By November 2026, the company had announced a $130 million Series D financing, bringing total disclosed funding to roughly $330 million across the rounds surfaced in public sources [PRNewswire] [Crunchbase] [Finsmes, Nov 2026].

One source, partially checked -- Core company identity is supported by the company website and Crunchbase, while the merger framing and financing chronology in this section rely partly on Crunchbase News and later financing coverage.

The Product and the Stack

Public record plus analysis

Galvanize’s product story is unusually clear for a late-stage private medtech company: the commercial wedge is pulsed electric field, or PEF, applied to soft-tissue ablation rather than thermal energy modalities [Galvanize Therapeutics, retrieved] [Citybiz, Nov 2026]. The company says its principal commercial platform, Aliya, delivers brief, high-voltage electrical pulses intended to induce nonthermal regulated cell death in soft tissue, and it states that the Aliya PEF System is cleared in the United States under FDA 510(k) clearances K212871, K233884, and K253826 for the surgical ablation of soft tissue [Galvanize Therapeutics, retrieved]. Public reporting also indicates that a next-generation Aliya EX Generator received FDA clearance in 2026 and began commercial procedures in August 2026, which suggests the company is already iterating on the installed platform rather than selling a single static device generation [Dealroom, Nov 2026].

The second platform broadens the clinical ambition beyond oncology. Reporting says RheOx applies PEF energy to the airways for chronic bronchitis [PUBLIC] [StartupsRaised, Nov 2026], and public clinical-study records describe a RheSolve pivotal study as a prospective, randomized, parallel-group, double-blind, sham-controlled, multicenter trial with follow-up to two years [PUBLIC] [American Lung Association] alongside another study, NCT05641207, evaluating the RheOx system in adult moderate to severe COPD patients with chronic bronchitis symptoms [PUBLIC] [ClinicalTrials.gov]. On the Aliya side, Galvanize announced the AFFINITY U.S. study in September 2023 for stage IV non-small cell lung cancer or metastasis to the lung, including first-patient treatment via an endobronchial approach with robotic-assisted navigation [PUBLIC] [PRNewswire, Sep 2023]. Taken together, the public record supports a two-platform architecture: one commercial soft-tissue ablation system with expanding evidence generation, and one airway-focused investigational platform still being worked through pivotal-style clinical development [Galvanize Therapeutics, retrieved] [PRNewswire, Sep 2023] [American Lung Association].

The technical stack is only partly visible from public materials, but the operating emphasis is easier to read. Galvanize’s site and financing coverage frame the products as energy-delivery systems engineered around PEF biology rather than as software-led workflow tools [Galvanize Therapeutics, retrieved] [MedTech Dive]. Hiring activity points in the same direction: open roles include Clinical Study Manager, Sr. Principal Clinical Research Associate, and Sr. Clinical Scientist, which is consistent with a company putting capital into multicenter trial execution, regulatory-grade evidence generation, and field clinical support rather than a broad digital-health buildout [Rippling] [Himalayas, retrieved 2026]. Any deeper claim about software architecture would be speculative from the available record, so the conservative read is that software is present inside a regulated device workflow, but the differentiation described publicly rests on the energy modality, clearance footprint, and accumulating procedure volume, not on an independently marketed software layer [Galvanize Therapeutics, retrieved] [Finsmes, Nov 2026].

One source, partially checked -- Product positioning is supported by the company website and press coverage, while several capability and clinical-development details rely on single-source public records or company-linked announcements.

The Market They Are Entering

PUBLIC

This market matters now because pulsed electric field ablation sits at the intersection of two large spend pools, procedural oncology and chronic airway disease, while the evidence base for newer nonthermal energy modalities is still being built in public view [ClinicalTrials.gov] [American Lung Association] [PRNewswire, September 2023].

The public record here is stronger on clinical direction than on market sizing. Galvanize is advancing Aliya in soft-tissue ablation and lung-focused studies, while RheOx is being studied for chronic bronchitis symptoms in moderate to severe COPD patients [Galvanize Therapeutics] [ClinicalTrials.gov] [PRNewswire, September 2023]. That places the company across at least two adjacent care pathways: interventional oncology, where hospitals already budget for ablation-capable capital equipment and procedure volumes, and pulmonary intervention, where chronic disease therapies are judged over longer follow-up windows and randomized evidence tends to matter more for adoption [ClinicalTrials.gov] [American Lung Association].

Because no named third-party TAM, SAM, or SOM figures were captured in the source set, the sizing discussion has to stay narrow. What can be said from public evidence is that Galvanize is not pursuing a single-indication niche. AFFINITY is evaluating Aliya in Stage IV non-small cell lung cancer or metastasis to the lung, and a separate study is evaluating Aliya for pulmonary lesions before planned surgical resection [PRNewswire, September 2023] [MedPath Trial]. In parallel, RheOx is in a pivotal chronic bronchitis program and another chronic bronchitis study on ClinicalTrials.gov, which suggests the company is targeting both oncologic and chronic pulmonary use cases rather than one reimbursement lane [American Lung Association] [ClinicalTrials.gov].

The near-term demand drivers are more visible than the addressable market math. Public filings and announcements point to three: physician interest in nonthermal tissue ablation, the need for evidence generation in real-world and pivotal settings, and product iteration that supports broader commercial use [Citybiz, November 2026] [ClinicalTrials.gov] [Dealroom, November 2026]. Galvanize reported more than 4,000 procedures using Aliya by November 2026, and the PROPEL registry had enrolled more than 300 patients, with Duke materials describing the registry as a multi-center effort at up to 25 U.S. sites [Finsmes, November 2026] [Citybiz, November 2026] [Scholars@Duke]. Those numbers do not size the market, but they do indicate that hospital adoption and clinician workflow testing are moving beyond first-in-human territory.

The substitute set is broad, even if named competitors were not captured in the source pack. For oncology, Aliya is competing for budget and physician attention against incumbent soft-tissue ablation approaches and against surgical or bronchoscopic workflows already used for lung lesions, since AFFINITY is specifically studying endobronchial delivery with robotic-assisted navigation [PRNewswire, September 2023]. For chronic bronchitis, RheOx sits adjacent to other device-based pulmonary interventions and to standard COPD symptom-management pathways, which means clinical benefit, durability, and procedural burden are likely to matter as much as the core energy modality [American Lung Association] [ClinicalTrials.gov].

Regulation is a gating force rather than a background detail in this category. On the commercial side, Aliya is marketed with U.S. 510(k) clearances for surgical ablation of soft tissue, including the Aliya EX Generator clearance reported in 2026 [Galvanize Therapeutics] [Dealroom, November 2026]. On the pipeline side, both the PROPEL registry and RheSolve pivotal study show that broader adoption still depends on accumulating post-clearance and trial evidence, especially when the target moves from general soft-tissue ablation toward specific pulmonary oncology or chronic bronchitis claims [ClinicalTrials.gov] [Scholars@Duke] [American Lung Association]. In practice, that tends to lengthen commercial ramps but can also create a clearer moat if outcomes data hold up.

Market lens Public evidence Why it matters
Soft-tissue ablation Aliya is cleared in the U.S. for surgical ablation of soft tissue [Galvanize Therapeutics] Indicates an existing commercial entry point rather than a pre-clearance platform.
Lung oncology adjacency AFFINITY began in the U.S. in September 2023 for Stage IV NSCLC or metastasis to the lung [PRNewswire, September 2023] Expands the platform toward a higher-acuity procedural oncology workflow.
Chronic bronchitis adjacency RheOx is being evaluated in RheSolve and another chronic bronchitis study [American Lung Association] [ClinicalTrials.gov] Adds a second disease area with a distinct evidence and adoption path.
Real-world evidence buildout PROPEL had enrolled more than 300 patients and is described as a multi-center registry at up to 25 U.S. sites [Citybiz, November 2026] [Scholars@Duke] Suggests the company is investing in adoption-supporting evidence, not only regulatory milestones.

The table points to a platform strategy more than a single-product market. That can expand the eventual opportunity, but it also means investors should expect the market story to remain evidence-led until indication-specific outcomes and usage patterns become clearer in public data.

One source, partially checked -- Based primarily on company materials, clinical trial registries, and single-source financing coverage; no independent third-party market size reports were captured in the source set.

The Competitive Field

Competitive map

MIXED Galvanize appears positioned less against a clearly disclosed set of direct public peers than against a broader field of soft-tissue ablation methods and chronic airway interventions, which is notable because the public record here is much stronger on product and financing than on named head-to-head rivals [Galvanize Therapeutics, retrieved] [DFXIntel, retrieved] [Finsmes, Nov 2026].

That leaves the competitive map to be drawn by segment. In soft-tissue ablation, the practical comparison set is not just other pulsed electric field platforms, but incumbent thermal approaches used by physicians and hospitals, because Galvanize describes Aliya as a nonthermal surgical ablation system rather than a general-purpose energy platform [Galvanize Therapeutics, retrieved] [Citybiz, retrieved]. In chronic bronchitis, RheOx sits in a different contest entirely, one centered on interventional pulmonary care and sham-controlled evidence generation, with the company still in study mode rather than claiming broad commercial leadership [American Lung Association, retrieved 2026] [ClinicalTrials.gov, retrieved 2026].

The company does have a visible edge today, but it is narrower than a casual reading of the funding headlines might suggest. Aliya has U.S. 510(k) clearances for soft-tissue surgical ablation, and by November 2026 public reports said the platform had been used in more than 4,000 procedures, while the PROPEL registry had enrolled more than 300 patients [Galvanize Therapeutics, retrieved] [Finsmes, Nov 2026] [Citybiz, retrieved]. That combination, clearance plus early commercial use plus real-world registry buildout, creates a factual base that many earlier-stage device companies do not yet have, although the durability of that edge depends on whether procedure growth converts into durable physician workflow adoption rather than remaining an early evidence-generation story [ClinicalTrials.gov, retrieved 2026] [Scholars@Duke, retrieved 2026].

The defensibility is therefore partly regulatory and partly capital-based. Galvanize has raised roughly $330 million across disclosed rounds, including a $130 million Series D in November 2026 led by HealthQuest Capital, with repeat support from major healthcare investors including Sofinnova Partners and Norwest [PRNewswire, retrieved] [Finsmes, Nov 2026] [Crunchbase News, Nov 2022]. In medtech, that matters because capital funds clinical follow-up, physician training, field support, and post-clearance evidence, but it is also perishable: capital helps sustain a launch, yet does not by itself secure a procedure category if outcomes, workflow fit, or reimbursement traction stall.

Galvanize is most exposed where the public evidence remains indirect. The company has not publicly surfaced named hospital customers in the source set, and the available material does not identify a public roster of direct competitors, which makes channel strength and share position difficult to verify independently [DFXIntel, retrieved]. The sharper risk is segment split. Aliya in oncology and RheOx in chronic bronchitis ask the company to compete in two adjacent but distinct clinical markets, each with its own evidence burden, specialist buyer, and adoption curve, so execution can dilute if one platform demands disproportionate commercial and clinical resources.

Over the next 18 months, the most plausible competitive scenario is bifurcation by evidence. Galvanize is the likely winner if Aliya's installed clinical base and registry data continue to compound into stronger physician confidence, especially after the 2026 clearance and August 2026 commercial start of the Aliya EX Generator [Dealroom, retrieved] [Citybiz, retrieved]. Galvanize is also the likely loser if the chronic bronchitis program absorbs capital and attention without producing sufficiently persuasive trial progress, because RheOx remains in pivotal and clinical-study territory in the public record rather than in scaled commercialization [LinkedIn, retrieved 2026] [American Lung Association, retrieved 2026] [ClinicalTrials.gov, retrieved 2026].

Opportunity

PUBLIC The prize here is not a single-device franchise, but a durable pulsed electric field platform that could matter across oncology and chronic airway disease if Galvanize keeps converting clinical momentum into standard hospital workflow [Galvanize Therapeutics, retrieved] [Finsmes, Nov 2026] [American Lung Association] [ClinicalTrials.gov].

The headline opportunity is straightforward. Galvanize could plausibly become one of the better-positioned independent PEF companies in soft-tissue ablation if Aliya continues to scale commercially while RheOx matures into a second clinical pillar [Galvanize Therapeutics, retrieved] [Dealroom] [StartupsRaised] [ClinicalTrials.gov]. That is reachable, rather than merely aspirational, because there is already evidence of three things that usually have to arrive in sequence: a cleared commercial product in the U.S., early real-world procedural volume, and an active pipeline of registries and trials that can widen physician confidence over time [Galvanize Therapeutics, Nov 2026] [Finsmes, Nov 2026] [Citybiz, Nov 2026] [PRNewswire, Sep 2023]. More than 4,000 procedures had been performed using Aliya by November 2026, the PROPEL registry had enrolled more than 300 patients, and the company is advancing a sham-controlled pivotal program for RheOx in chronic bronchitis, which suggests this is already beyond a concept-stage platform story [Finsmes, Nov 2026] [Citybiz, Nov 2026] [American Lung Association].

A reasonable way to think about the upside is through a small set of distinct growth paths, each with a visible catalyst in the public record.

Scenario What happens Catalyst Why it's plausible
Aliya becomes a standard soft-tissue ablation option Aliya expands from early oncology use into a broader U.S. hospital and physician workflow for soft-tissue ablation Additional clinical evidence from AFFINITY and ongoing commercial rollout of the Aliya EX Generator Aliya is already cleared in the U.S., the EX Generator received FDA clearance in 2026, and more than 4,000 procedures had been completed by November 2026 [Galvanize Therapeutics, retrieved] [Dealroom] [Finsmes, Nov 2026]
Dual-platform medtech company The company builds a second meaningful revenue engine if RheOx proves effective in chronic bronchitis and reaches commercialization Readouts and regulatory progress from the RheSolve pivotal study and related chronic bronchitis trials RheOx is already in pivotal evaluation, and the RheSolve study had enrolled its 270th patient according to company-linked reporting [LinkedIn] [American Lung Association] [ClinicalTrials.gov]
Evidence-led category leader in PEF lung applications Galvanize becomes the reference operator for endobronchial and pulmonary PEF use cases, supporting both procedure growth and future indications Positive safety and local-control data from AFFINITY and continued registry buildout through PROPEL The company started AFFINITY in 2023, reported first-patient treatment in the U.S., and Interventional News cited positive six-month results on safety and local control [PRNewswire, Sep 2023] [Interventional News] [Citybiz, Nov 2026]

The scenarios are notable because they stack rather than compete. Aliya's commercial installed-base logic can fund and de-risk broader evidence generation, while every additional treated case and registry enrollee can make the sales motion less about novel physics and more about documented workflow and outcomes [Finsmes, Nov 2026] [Citybiz, Nov 2026]. The early signs of compounding are visible in sequence: FDA clearances created a sellable product, commercial procedures created operator familiarity, the PROPEL registry created a mechanism for real-world evidence, and next-generation hardware in the Aliya EX Generator gives the company a reason to revisit accounts with an upgraded offering [Galvanize Therapeutics, retrieved] [Dealroom] [ClinicalTrials.gov].

What compounding looks like in practice is not a consumer-style network effect, but a medtech evidence and adoption flywheel. More procedures can produce more physician experience and more registry data; more data can support stronger case-making to hospitals and interventional teams; broader use can justify adjacent trials such as AFFINITY and pulmonary lesion studies, which in turn can widen the addressable clinical map for the same underlying energy modality [Citybiz, Nov 2026] [PRNewswire, Sep 2023] [MedPath Trial] [ClinicalTrials.gov]. If RheOx also advances, Galvanize would own two shots on goal built on a common PEF competency, which is often where category platforms in medical devices become strategically valuable [StartupsRaised] [American Lung Association].

The size of the win is hard to anchor precisely from the public record because no valuation or third-party market-size benchmark is confirmed in the supplied sources. Even so, the disclosed capital base is large enough to frame ambition: roughly $330 million in disclosed financing across the Series B, Series C, and Series D suggests investors are underwriting a company that could support multiyear commercialization and clinical expansion rather than a narrow single-product exit [Crunchbase News, Nov 2022] [StartupsRaised] [PRNewswire, Nov 2026]. If the dual-platform scenario plays out, with Aliya establishing a durable oncology and soft-tissue ablation footprint and RheOx reaching market, the outcome could resemble a scaled independent medtech platform rather than an asset sale, which would support multibillion-dollar enterprise value potential (scenario, not a forecast). Public evidence here supports the shape of that upside, but not a precise valuation range.

One source, partially checked -- This section relies on one or more independent public sources for most operating claims, with several important product and pipeline details still dependent on company materials or single-source trade coverage.

Sources

Publicly reported

  1. [Galvanize Therapeutics, retrieved] About Galvanize Therapeutics | https://galvanizetx.com/about/

  2. [PRNewswire, Nov 2026] Galvanize Therapeutics, Inc. Announces Oversubscribed $130 Million Series D Financing | https://www.prnewswire.com/news-releases/galvanize-therapeutics-inc-announces-oversubscribed-130-million-series-d-financing-302508644.html

  3. [Crunchbase News, Nov 2022] Galvanize Therapeutics Merges 3 Companies, Nabs $100M | https://news.crunchbase.com/health-wellness-biotech/venture-capital-fundraising-medical-galvanize/

  4. [Finsmes, Nov 2026] Galvanize Therapeutics Raises $130M in Series D Financing | https://www.finsmes.com/2026/11/galvanize-therapeutics-raises-130m-in-series-d-financing.html

  5. [Galvanize Therapeutics, Nov 2026] Galvanize Therapeutics® | https://galvanizetx.com/

  6. [Apple Tree Partners, retrieved] Apple Tree Partners News | https://www.appletreepartners.com/news/412

  7. [StartupsRaised, Nov 2026] Galvanize Therapeutics Raises Series D Plus | https://www.startupsraised.com/news/galvanize-therapeutics-raises-series-d-plus

  8. [DFXIntel, retrieved] Galvanize Therapeutics raises $130 million Series D led by HealthQuest | https://dfxintel.com/data-factory/intelligence/story/galvanize-therapeutics-raises-130-million-series-d-led-by-healthquest-e05991

  9. [ClinicalTrials.gov, retrieved 2026] ClinicalTrials.gov study record | https://clinicaltrials.gov/

  10. [American Lung Association, retrieved 2026] American Lung Association clinical trial record | https://www.lung.org/

  11. [Crunchbase, retrieved 2026] Galvanize Therapeutics | https://www.crunchbase.com/organization/galvanize-therapeutics

  12. [Dealroom, Nov 2026] Galvanize raises $130M Series D for pulsed field expansion | https://dealroom.co/news/173060-galvanize-raises-130m-series-d-for-pulsed-field-expansion/

  13. [MedTech Dive, retrieved] Galvanize raises $130M to advance pulsed electric field ablation | https://www.medtechdive.com/news/galvanize-raises-130m-to-advance-pulsed-electric-field-ablation/874861/

  14. [Rippling, retrieved] Galvanize Therapeutics jobs | https://ats.rippling.com/galvanizetherapeutics/jobs/5f772071-8a4d-4a91-b65d-e2419f373dce

  15. [Himalayas, retrieved 2026] Clinical Study Manager at Galvanize Therapeutics | https://himalayas.app/companies/galvanize-therapeutics/jobs/clinical-study-manager

  16. [Citybiz, Nov 2026] T. Rowe Price-Backed Galvanize Therapeutics Secures $130M Led by HealthQuest | https://www.citybiz.co/article/934423/t-rowe-price-backed-galvanize-therapeutics-secures-130m-led-by-healthquest/

  17. [PRNewswire, Sep 2023] Galvanize Therapeutics Announces Commencement of AFFINITY Clinical Study and First Patient Treated in U.S. | https://www.prnewswire.com/news-releases/galvanize-therapeutics-announces-commencement-of-affinity-clinical-study-and-first-patient-treated-in-us-301920508.html

  18. [MedPath Trial, retrieved 2026] NCT07487064 trial record | https://trial.medpath.com/clinical-trial/0b99d34d64d9dd1d

  19. [Scholars@Duke, retrieved 2026] PROPEL registry abstract | https://scholars.duke.edu/

  20. [Interventional News, retrieved 2026] Positive six-month AFFINITY results for Aliya PEF ablation system | https://interventionalnews.com/

  21. [LinkedIn, retrieved 2026] LinkedIn profile | https://www.linkedin.com/in/seth-harrison-0707b0b0/

Articles about Galvanize Therapeutics

View on Startuply.vc